 |
|
|
|
July 2000 Cover
|
|
Researchers have found that once a day treatment with angiogenesis inhibitor col-3 generated a response in 33 percent of patients with AIDS-related Kaposi's sarcoma (KS). The study of 18 patients with KS found a grade
3 or 4 toxicity, and one third of the patients had positive responses. Seven patients left the trial because of adverse effects, which included photosensitivity and headache. The researchers noted that overall incidence of
serious side effects was low.
Editor's Note: from Reuters Health Info Services
You are not logged in.
No comments yet, but
click here to be the first to comment on this
HIV Digest!
|
|
|
|
|
